
    
      Endpoints are to describe: the proportion of patients with local control for the index site
      at 1 year; the number of index lesion(s) with local control at 1 year; acute and late AEs
      related to SBRT; time to local progression for the index site; time to distant disease
      progression; symptom and QoL profile; median survival.
    
  